| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/15/2011 | CA2377085C Substituted benzimidazoles |
| 02/15/2011 | CA2356701C Gene therapy for diabetic ischemic disease |
| 02/15/2011 | CA2263647C Stable non-hygroscopic crystalline form of n-[n-n-(4-(piperidin-4-yl)butanoyl)-n-ethylglycyl] compounds |
| 02/10/2011 | WO2011017554A2 Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome |
| 02/10/2011 | WO2011017533A1 Crystalline salts of methyl 2- ( (r) - ( 3-chloro phenyl) ( (r) -l- ( (s) -2- (methylamino) -3- ( (r) -tetrahydro-2h-pyran-3-yl) propylcarbamoyl ) |
| 02/10/2011 | WO2011017108A2 Cyclopropyl modulators of p2y12 receptor |
| 02/10/2011 | WO2011016686A2 Prasugrel disulfonate or crystalline forms thereof, method for preparing same, and pharmaceutical composition containing same |
| 02/10/2011 | WO2011016652A2 Composition for controlling anal fistulae and method for preparing same |
| 02/10/2011 | WO2011016561A1 Dna capable of inducing osteoblast-specific expression, and nucleotide sequence for same |
| 02/10/2011 | WO2011016501A1 Prophylactic or therapeutic agent for cancer |
| 02/10/2011 | WO2011016472A1 Pyridine and pyrimidine derivatives having ttk-inhibiting activity |
| 02/10/2011 | WO2011016461A1 Tumor angiogenesis inhibitor |
| 02/10/2011 | WO2011016459A1 Thienooxazepine derivative |
| 02/10/2011 | WO2011016366A1 Cholesterol ester transfer protein inhibitor |
| 02/10/2011 | WO2011015629A1 Derivatives of 2h pyridazin- 3 -ones, their preparation and their use as scd-1 inhibitors |
| 02/10/2011 | US20110035818 Diagnostic marker and platform for drug design in myocardial infarction and heart failure |
| 02/10/2011 | US20110034867 Microthread delivery system |
| 02/10/2011 | US20110034568 Compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
| 02/10/2011 | US20110034566 Long term drug delivery devices with polyurethane based polymers and their manufacture |
| 02/10/2011 | US20110034564 Soluble complexes of curcumin |
| 02/10/2011 | US20110034563 Compartment-specific plant extract combination of ginkgo biloba extract and ginseng extract having a tandem effect |
| 02/10/2011 | US20110034534 siRNA compounds and methods of use thereof |
| 02/10/2011 | US20110034527 Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
| 02/10/2011 | US20110034526 Benzimidazole Compounds |
| 02/10/2011 | US20110034525 Nonsedating alpha-2 agonists |
| 02/10/2011 | US20110034516 Aminopyrazole derivatives |
| 02/10/2011 | US20110034514 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors |
| 02/10/2011 | US20110034505 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators |
| 02/10/2011 | US20110034504 Agent for preventing and/or treating vascular diseases |
| 02/10/2011 | US20110034500 Spiroheterocyclic compounds and their uses as therapeutic agents |
| 02/10/2011 | US20110034499 Spiroindolines as modulators of chemokine receptors |
| 02/10/2011 | US20110034487 Cxcr3 antagonists |
| 02/10/2011 | US20110034485 Nitrone compounds, process of preparation thereof, and use thereof in medicament manufacture |
| 02/10/2011 | US20110034468 Triazolo compounds useful as dgat1 inhibitors |
| 02/10/2011 | US20110034461 Sf5 derivatives as par1 inhibitors, production thereof, and use as medicaments |
| 02/10/2011 | US20110034458 Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors |
| 02/10/2011 | US20110034456 Imidazopyridazines as par1 inhibitors, production thereof, and use as medicaments |
| 02/10/2011 | US20110034455 Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| 02/10/2011 | US20110034454 Morpholino pyrimidine derivatives and their use in therapy |
| 02/10/2011 | US20110034452 Triazolium salts as par1 inhibitors, production thereof, and use as medicaments |
| 02/10/2011 | US20110034451 Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments |
| 02/10/2011 | US20110034450 Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof |
| 02/10/2011 | US20110034448 Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
| 02/10/2011 | US20110034440 Homocysteine synthase inhibitor |
| 02/10/2011 | US20110034437 Isoxazolines as inhibitors of fatty acid amide hydrolase |
| 02/10/2011 | US20110034433 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use |
| 02/10/2011 | US20110034419 Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease |
| 02/10/2011 | US20110034409 Use of pharmaceutical compound in the treatment of wounds |
| 02/10/2011 | US20110034395 Compositions and methods of inhibiting apoptosis |
| 02/10/2011 | US20110034391 Shaped article |
| 02/10/2011 | US20110034387 Polypeptide inhibiting angiogenesis and application thereof |
| 02/10/2011 | US20110034383 Cxcl12 gamma a chemokine and uses thereof |
| 02/10/2011 | US20110034380 Combination of a selective ppar-gamma modulator and an incretin for the treatment of diabetes and obesity |
| 02/10/2011 | US20110034378 Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. |
| 02/10/2011 | US20110034377 Exendin and Exendin Agonists for Eating Disorders |
| 02/10/2011 | US20110033548 Degradable crosslinked aminated dextran microspheres and methods of use |
| 02/10/2011 | US20110033533 Galenical formulations of organic compounds |
| 02/10/2011 | US20110033531 Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof |
| 02/10/2011 | US20110033521 Molecules and Methods of Using Same for Treating MCP-1/CCR2 Associated Diseases |
| 02/10/2011 | US20110033518 Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase |
| 02/10/2011 | US20110033505 Methods and compositions for treatment of ion imbalances |
| 02/10/2011 | US20110033469 Leukotriene b4 binding soluble lipocalin receptor from ixodes ricinus |
| 02/10/2011 | US20110033465 Anti-pcsk9 and methods for treating lipid and cholesterol disorders |
| 02/10/2011 | US20110033444 Genetic variants in a hypertension susceptibility gene Stk39 and uses thereof |
| 02/10/2011 | US20110033434 Cultured three-dimensional tissues and uses thereof |
| 02/10/2011 | US20110033430 Methods for the induction of a cell to enter the islet 1+ lineage and a method for the expansion thereof |
| 02/10/2011 | US20110033414 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition |
| 02/10/2011 | CA2768043A1 Cyclopropyl modulators of p2y12 receptor |
| 02/09/2011 | EP2281828A2 Compositions comprising modified erythropoietin |
| 02/09/2011 | EP2281818A1 Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient |
| 02/09/2011 | EP2281578A2 Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer |
| 02/09/2011 | EP2281569A1 Use of prourokinase and variants thereof in facilitated percutaneous coronary intervention in patients with acute myocardial infarction |
| 02/09/2011 | EP2281040A2 Lyophilized dna formulations for enhanced expression of plasmid dna |
| 02/09/2011 | EP2281007A2 Anti-atheroma vaccine |
| 02/09/2011 | EP2280983A2 C-aryl glycoside compounds for the treatment of diabetes and obesity |
| 02/09/2011 | EP2280948A1 Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers. |
| 02/09/2011 | EP2280946A1 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
| 02/09/2011 | EP2280935A1 4-trimethylammonio-butyrates as cpt2 inhibitors |
| 02/09/2011 | EP2280928A2 Vinyl substituted fatty acids |
| 02/09/2011 | EP2280732A2 Antibodies to granulocyte-macrophage colony-stimulating factor |
| 02/09/2011 | EP2280702A2 Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood |
| 02/09/2011 | EP2280701A2 Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
| 02/09/2011 | EP2280700A2 Combination of dronedarone with at least one diuretic, and therapeutic use thereof |
| 02/09/2011 | EP2280695A1 Hydroxytyrosol benefits mitochondria |
| 02/09/2011 | EP2051722B1 Method for treating diabetic vascular complications |
| 02/09/2011 | EP1943251B1 A1 adenosine receptor agonists |
| 02/09/2011 | EP1874140B1 Peptides having a health benefit and compositions comprising them |
| 02/09/2011 | EP1819227B1 Pharmaceutical formulation of decitabine |
| 02/09/2011 | EP1716869B1 Drug for preventing or treating heart diseases comprising cd9 gene |
| 02/09/2011 | EP1559426B1 Percutaneous absorption preparations containing 3-methyl-1-phenyl-2-pyrazolin-5-one |
| 02/09/2011 | EP1459738B1 Pharmaceutical composition having thrombolytic, anti-inflammatory and cytoprotective properties |
| 02/09/2011 | EP1370276B1 Intercellular communication facilitating compounds and their medical use |
| 02/09/2011 | EP0848755B2 Vegf-related protein |
| 02/09/2011 | CN201734975U Heart-shaped special-shaped tablet |
| 02/09/2011 | CN1827638B Vancomycin and nor-vancomycin derivatives and their preparation process and use |
| 02/09/2011 | CN101970441A Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors |
| 02/09/2011 | CN101970437A Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals |
| 02/09/2011 | CN101970414A 1 ibeta-hydroxysteroid dehydrogenase inhibitors |
| 02/09/2011 | CN101970051A Rna interference for the treatment of heart failure |
| 02/09/2011 | CN101970007A Therapeutic or prophylactic agent for cerebral aneurysm |